Melanoma update: Diagnostic and prognostic factors that can effectively shape and personalize management

Biomarkers in Medicine

Volumn 5, Issue 3, 2011, Pages 333-360

  Linos, Konstantinos ^a   Slominski, Andrzej ^b   Ross, Jeffrey S ^a   Carlson, J Andrew ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

American Joint Commission on Cancer 2009 staging of melanoma; diagnosis; management; melanoma; prognosis; staging; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; GSK 2118436; IPILIMUMAB; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; STEM CELL FACTOR RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; CANCER TEST; CARCINOMA IN SITU; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME MARKER; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GNA11 GENE; GNAQ GENE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SPINDLE CELL CARCINOMA;

BIOLOGICAL MARKERS; CHROMOSOMAL INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; MELANOMA; MUTATION; NEOPLASM STAGING; PROGNOSIS;

EID: 79958825792     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.39     Document Type: Review

References (281)

1. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 365(9460), 687-701 (2005). (Pubitemid 40260892)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009 CA Cancer J. Clin. 59(4), 225-249 (2009).
3. Carlson JA, Ross JS, Slominski AJ: New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin. Dermatol. 27(1), 75-102 (2009).
4. Beddingfield FC 3rd: The melanoma epidemic: res ipsa loquitur. Oncologist 8(5), 459-465 (2003). (Pubitemid 37238874)
5. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC: Economic burden of melanoma in the elderly population: population-based analysis of the surveillance, epidemiology, and end results (SEER)-medicare data. Arch. Dermatol. 146(3), 249-256 (2010).
6. Tawbi HA, Kirkwood JM: Management of metastatic melanoma. Semin. Oncol. 34(6), 532-545 (2007). (Pubitemid 350236308)
7. Meyskens FL Jr, Farmer PJ, Yang S, Anton-Culver H: New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 174, 191-195 (2007).
8. Berwick M, Wiggins C: The current epidemiology of cutaneous malignant melanoma. Front. Biosci. 11, 1244-1254 (2006). (Pubitemid 43253416)
9. Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS: Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev. Mol. Diagn. 3(2), 163-184 (2003). (Pubitemid 36313750)
10. Armstrong BK, Kricker A: The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B 63(1-3), 8-18 (2001). (Pubitemid 33040718)
11. Curtin JA, Busam K, Pinkel D, Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340-4346 (2006). (Pubitemid 46630793)
12. Curtin JA, Fridlyand J, Kageshita T et al.: Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005). (Pubitemid 41653105)
13. Bauer J, Buttner P, Murali R et al.: BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 24(2), 345-351 (2011).
14. Veierod MB, Weiderpass E, Thorn M et al.: A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J. Natl Cancer Inst. 95(20), 1530-1538 (2003). (Pubitemid 37322096)
15. Dore JF, Pedeux R, Boniol M, Chignol MC, Autier P: Intermediate-effect biomarkers in prevention of skin cancer. IARC Sci. Publ. 154, 81-91 (2001).
16. Brozyna A, Zbytek B, Granese J, Carlson JA, Ross J, Slominski A: Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. Expert Rev. Dermatol. 2(4), 451-469 (2007). (Pubitemid 47263371)
17. Naldi L, Altieri A, Imberti GL, Gallus S, Bosetti C, La Vecchia C: Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy).Cancer Causes Control 16(8), 893-899 (2005). (Pubitemid 41191415)
18. Andersen WK, Labadie RR, Bhawan J: Histopathology of solar lentigines of the face: a quantitative study. J. Am. Acad. Dermatol. 36(3 Pt 1), 444-447 (1997). (Pubitemid 27131970)
19. Kossard S: Atypical lentiginous junctional naevi of the elderly and melanoma. Australas J. Dermatol. 43(2), 93-101 (2002).
20. Arumi-Uria M, Mcnutt NS, Finnerty B: Grading of atypia in nevi: correlation with melanoma risk. Mod. Pathol. 16(8), 764-771 (2003). (Pubitemid 37011071)
21. Lee DA, Miller SJ: Nonmelanoma skin cancer. Facial Plast. Surg. Clin. North Am. 17(3), 309-324 (2009).
22. Madan V, Lear JT, Szeimies RM: Non-melanoma skin cancer. Lancet 375(9715), 673-685 (2010).
23. Tolleson WH: Human melanocyte biology, toxicology, and pathology. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 23(2), 105-161 (2005). (Pubitemid 41565452)
24. Rohwedder A, Philips B, Malfetano J, Kredentser D, Carlson JA: Vulvar malignant melanoma associated with human papillomavirus DNA: report of two cases and review of literature. Am. J. Dermatopathol. 24(3), 230-240 (2002). (Pubitemid 34587253)
25. Rohwedder A, Slominski A, Wolff M, Kredentser D, Carlson JA: Epidermodysplasia verruciformis and cutaneous human papillomavirus DNA, but not genital human papillomavirus DNAs, are frequently detected in vulvar and vaginal melanoma. Am. J. Dermatopathol. 29(1), 13-17 (2007). (Pubitemid 46220233)
26. Ragnarsson-Olding BK: Spatial density of primary malignant melanoma in sun-shielded body sites: a potential guide to melanoma genesis. Acta Oncologica 50(3), 323-328 (2011).
27. Lipsker D, Engel F, Cribier B, Velten M, Hedelin G: Trends in melanoma epidemiology suggest three different types of melanoma. Br. J. Dermatol. 157(2), 338-343 (2007). (Pubitemid 47083865)
28. Martorell-Calatayud A, Nagore E, Botella- Estrada R et al.: Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features. Melanoma Res. 21(2), 131-138 (2011).
29. Tejera-Vaquerizo A, Barrera-Vigo MV, Lopez-Navarro N, Herrera-Ceballos E: Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J. Eur. Acad. Dermatol. Venereol. 24(2), 147-154 (2010).
30. Criscione VD, Weinstock MA: Melanoma thickness trends in the United States, 1988-2006. J. Invest. Dermatol. 130(3), 793-797 (2010).
31. Levell NJ, Beattie CC, Shuster S, Greenberg DC: Melanoma epidemic: a midsummer night's dream? Br. J. Dermatol. 161(3), 630-634 (2009).
32. Newton Bishop JA, Gruis NA: Genetics: what advice for patients who present with a family history of melanoma? Semin. Oncol. 34(6), 452-459 (2007). (Pubitemid 350236306)
33. Bishop JN, Bataille V, Gavin A et al.: The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin. Med. 7(3), 283-290 (2007). (Pubitemid 46998762)
34. Singh H, Sethi S, Raber M, Petersen LA: Errors in cancer diagnosis: current understanding and future directions. J. Clin. Oncol. 25(31), 5009-5018 (2007). (Pubitemid 350220435)
35. Clark WH Jr, Elder DE, Guerry DT et al.: Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989). (Pubitemid 20026075)
36. Carlson JA, Ross JS, Slominski A et al.: Molecular diagnostics in melanoma. J. Am. Acad. Dermatol. 52(5), 743-775 (2005). (Pubitemid 40614638)
37. Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS: Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev. Mol. Diagn. 3(3), 303-330 (2003). (Pubitemid 36612203)
38. Guitart J, Lowe L, Piepkorn M et al.: Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol. 138(5), 603-608 (2002).
39. Cook MG, Spatz A, Brocker EB, Ruiter DJ: Identification of histological features associated with metastatic potential in thin ((<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J. Pathol. 197(2), 188-193 (2002). (Pubitemid 34567606)
40. Mckinnon JG, Yu XQ, Mccarthy WH, Thompson JF: Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 98(6), 1223-1231 (2003). (Pubitemid 37099907)
41. Gimotty PA, Botbyl J, Soong SJ, Guerry D: A population-based validation of the American Joint Committee on cancer melanoma staging system. J. Clin. Oncol. 23(31), 8065-8075 (2005). (Pubitemid 46657409)
42. Balch CM, Buzaid AC, Soong SJ et al.: Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001). (Pubitemid 32786276)
43. Meier F, Will S, Ellwanger U et al.: Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147(1), 62-70 (2002). (Pubitemid 34779439)
44. Li Y, Mcclay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin.Oncol. 29(5), 413-426 (2002). (Pubitemid 35178281)
45. Lorigan P, Eisen T, Hauschild A: Systemic therapy for metastatic malignant melanoma - from deeply disappointing to bright future? Exp. Dermatol. 17(5), 383-394 (2008). (Pubitemid 351513952)
46. Linette GP, Carlson JA, Slominski A, Mihm MC, Ross JS: Biomarkers in melanoma: stage III and IV disease. Expert Rev. Mol. Diagn. 5(1), 65-74 (2005). (Pubitemid 40138769)
47. Davies MA, Gershenwald JE: Targeted therapy for melanoma: a primer. Surg. Oncol. Clin. N. Am. 20(1), 165-180 (2011).
48. Bielas JH, Loeb LA: Mutator phenotype in cancer: timing and perspectives. Environ. Mol. Mutagen 45(2-3), 206-213 (2005).
49. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
50. Nowell PC: Tumor progression: a brief historical perspective. Semin. Cancer Biol. 12(4), 261-266 (2002). (Pubitemid 35034570)
51. Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11(3), 220-228 (2010).
52. Hussein MR, Wood GS: Microsatellite instability and its relevance to cutaneous tumorigenesis. J. Cutan. Pathol. 29(5), 257-267 (2002). (Pubitemid 34828037)
53. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C: Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9(12), M57-M60 (1999).
54. Ushijima T: Epigenetic field for cancerization. J. Biochem. Mol. Biol. 40(2), 142-150 (2007). (Pubitemid 46515191)
55. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396(6712), 643-649 (1998). (Pubitemid 29003936)
56. Duesberg PH: Are cancers dependent on oncogenes or on aneuploidy? Cancer Genet. Cytogenet. 143(1), 89-91 (2003). (Pubitemid 36549013)
57. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA: Can chromosomal instability initiate tumorigenesis? Semin. Cancer Biol. 15(1), 43-49 (2005). (Pubitemid 40018527)
58. Pleasance ED, Cheetham RK, Stephens PJ et al.: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196 (2010).
59. Pleasance ED, Stephens PJ, O'meara S et al.: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010).
60. Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68(10), 3551-3557; discussion 3557 (2008).
61. Schollnberger H, Beerenwinkel N, Hoogenveen R, Vineis P: Cell selection as driving force in lung and colon carcinogenesis. Cancer Res. 70(17), 6797-6803 (2010).
62. Bozic I, Antal T, Ohtsuki H et al.: Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107(43), 18545-18550 (2010).
63. Rubin H: Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. Bioessays 33(3), 224-231 (2011).
64. Carlson JA, Murphy M, Slominski A, Wilson VL: Evidence of skin field cancerization. In:Field Cancerization: Basic Science and Clinical Applications , Dakubo G (Ed.).Nova Science Publishers, Hauppauge, New York, NY, USA (2011).
65. Kaur P, Mulvaney M, Carlson JA: Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am. J. Dermatopathol. 28(4), 293-307 (2006). (Pubitemid 44181566)
66. Carlson JA, Healy K, Tran TA et al.: Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. Am. J. Pathol. 157(3), 973-983 (2000). (Pubitemid 32109389)
67. Carlson JA, Amin S, Malfetano J et al.: Concordant p53 and mdm-2 protein expression in vulvar squamous cell carcinoma and adjacent lichen sclerosus. Appl. Immunohistochem. Mol. Morphol. 9(2), 150-163 (2001). (Pubitemid 32477203)
68. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R: Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch. Dermatol. 146(3), 288-293 (2010).
69. Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8(1), 1-12 (1954).
70. Ashton KJ, Carless MA, Griffiths LR: Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer 43(3), 239-248 (2005). (Pubitemid 40726869)
71. Boukamp P: Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 26(10), 1657-1667 (2005). (Pubitemid 41487981)
72. Blokx WA, Van Dijk MC, Ruiter DJ: Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. Histopathology 56(1), 121-132 (2010).
73. Dadzie OE, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M: RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br. J. Dermatol. 160(2), 368-375 (2009).
74. Zabierowski SE, Herlyn M: Melanoma stem cells: the dark seed of melanoma. J. Clin. Oncol. 26(17), 2890-2894 (2008).
75. Tucker MA, Fraser MC, Goldstein AM et al.: A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 94(12), 3192-3209 (2002). (Pubitemid 34670503)
76. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP: A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med. J. Aust. 167(4), 191-194 (1997). (Pubitemid 27387245)
77. Sell S: Cancer stem cells and differentiation therapy. Tumour Biol. 27(2), 59-70 (2006).
78. Bissell MJ, Hines WC: Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17(3), 320-329 (2011).
79. Bastian BC, Leboit PE, Hamm H, Brocker EB, Pinkel D: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58(10), 2170-2175 (1998). (Pubitemid 28232904)
80. Carless MA, Griffiths LR: Cytogenetics of melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol. 624, 227-240 (2008).
81. Crotty K, Mccarthy SW, Mihm M Jr: The histologic diagnosis and classification of melanoma. In:Textbook of Melanoma . Thompson JF, Morton DL, Kroon BB (Eds).Martin Dunitz, London, UK (2004).
82. Sagebiel RW: Pigmented lesion pathology: the specimen and its report. A personal and probably biased approach. Pathology (Phila.) 2(2), 281-298 (1994).
83. Banerjee SS, Harris M: Morphological and immunophenotypic variations in malignant melanoma. Histopathology 36(5), 387-402 (2000). (Pubitemid 30311621)
84. Kirkham N: Optimal handling and criteria for melanoma diagnosis. Histopathology 37(5), 467-469 (2000).
85. Cerroni L, Kerl H: Tutorial on melanocytic lesions. Am. J. Dermatopathol. 23(3), 237-241 (2001). (Pubitemid 32525418)
86. Shoo BA, Sagebiel RW, Kashani-Sabet M: Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J. Am. Acad. Dermatol. 62(5), 751-756 (2010).
87. Jackson R: Malignant melanoma: a review of 75 malpractice cases. Int. J. Dermatol. 36(7), 497-498 (1997). (Pubitemid 127746584)
88. Troxel DB: Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am. J. Surg. Pathol. 27(9), 1278-1283 (2003). (Pubitemid 37040591)
89. Van Dijk MC, Aben KK, Van Hees F et al.: Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. Histopathology 52(2), 139-146 (2008).
90. Cerroni L, Barnhill R, Elder D et al.: Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX symposium of the International Society of Dermatopathology in Graz, October 2008 Am. J. Surg. Pathol. 34(3), 314-326 (2010).
91. Barnhill RL: The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod. Pathol. 19(Suppl. 2), S21-S33 (2006). (Pubitemid 43172307)
92. Wechsler J, Bastuji-Garin S, Spatz A et al.: Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch. Dermatol. 138(5), 625-628 (2002).
93. Brochez L, Verhaeghe E, Grosshans E et al.: Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J. Pathol. 196(4), 459-466 (2002). (Pubitemid 34262859)
94. Lodha S, Saggar S, Celebi JT, Silvers DN: Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J. Cutan. Pathol. 35(4), 349-352 (2008). (Pubitemid 351363772)
95. Scolyer RA, Shaw HM, Thompson JF et al.: Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am. J. Surg. Pathol. 27(12), 1571-1576 (2003). (Pubitemid 37486620)
96. Elder DE, Murphy GF: Melanocytic Tumors of the Skin. (3rd Edition).American Registry of Pathology, Washington, DC, USA (1991).
97. Slater DN: Melanocytic intra-epidermal neoplasia (MIN).Histopathology 30(2), 195-197 (1997).
98. Elder DE, Xu X: The approach to the patient with a difficult melanocytic lesion. Pathology 36(5), 428-434 (2004). (Pubitemid 39273986)
99. Bastian BC: Molecular genetics of melanocytic neoplasia: practical applications for diagnosis. Pathology 36(5), 458-461 (2004). (Pubitemid 39273990)
100. Bauer J, Bastian BC: Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol. Ther. 19(1), 40-49 (2006).
101. Piris A, Mihm MC Jr: Progress in melanoma histopathology and diagnosis. Hematol. Oncol. Clin. North Am. 23(3), 467-480 (2009).
102. Ruiter D, Mooi W, Van Muijen GN, Cochran AJ: Immunohistochemistry and special diagnostic techniques. In:Textbook of Melanoma . Thompson JF, Morton DL, Kroon BB (Eds).Martin Dunitz, London, UK, 129-147 (2004).
103. Busam KJ: The use and application of special techniques in assessing melanocytic tumours. Pathology 36(5), 462-469 (2004). (Pubitemid 39273991)
104. Tuthill RJ, Reed RJ: Failure of senescence in the dysplasia-melanoma sequence: demonstration using a tissue microarray and a revised paradigm for melanoma. Semin. Oncol. 34(6), 467-475 (2007). (Pubitemid 350236313)
105. Gerami P, Jewell SS, Morrison LE et al.: Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am. J. Surg. Pathol. 33(8), 1146-1156 (2009).
106. Hammock L, Cohen C, Carlson G et al.: Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J. Cutan. Pathol. 33(9), 599-607 (2006). (Pubitemid 44370056)
107. Takata M, Suzuki T, Ansai S et al.: Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): its usefulness as an adjunctive diagnostic tool for melanocytic tumors. J. Dermatol. Sci. 40(1), 51-57 (2005). (Pubitemid 41383898)
108. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ: RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi. Mod. Pathol. 21(3), 326-333 (2008). (Pubitemid 351304287)
109. Gjerdrum LM, Abrahamsen HN, Villegas B, Sorensen BS, Schmidt H, Hamilton-Dutoit SJ: The influence of immunohistochemistry on mRNA recovery from microdissected frozen and formalin-fixed, paraffin-embedded sections. Diagn. Mol. Pathol. 13(4), 224-233 (2004). (Pubitemid 39552244)
110. Van Dijk MC, Rombout PD, Mooi WJ et al.: Allelic imbalance in the diagnosis of benign, atypical and malignant Spitz tumours. J. Pathol. 197(2), 170-178 (2002). (Pubitemid 34567604)
111. Dadzie OE, Neat M, Emley A, Bhawan J, Mahalingam M: Molecular diagnostics-an emerging frontier in dermatopathology. Am. J. Dermatopathol. 33(1), 1-13 (2011).
112. Wachsman W, Morhenn V, Palmer T et al.: Non-invasive genomic detection of melanoma. Br. J. Dermatol. 164(4), 797-806 (2011).
113. Slominski A: Coming of age of melanogenesis-related proteins. Arch. Pathol. Lab. Med. 126(7), 775-777 (2002). (Pubitemid 34761635)
114. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW: Immunohistochemical characteristics of melanoma. J. Cutan. Pathol. 35(5), 433-444 (2008). (Pubitemid 351519417)
115. Heintz PW, White CR Jr: Diagnosis: atypical fibroxanthoma or not? Evaluating spindle cell malignancies on sun damaged skin: a practical approach. Semin. Cutan. Med. Surg. 18(1), 78-83 (1999). (Pubitemid 29165102)
116. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL: Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 75(2), 478-494 (1995).
117. Kanik AB, Yaar M, Bhawan J: p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J. Cutan. Pathol. 23(3), 205-210 (1996). (Pubitemid 26181307)
118. Fanburg-Smith JC, Miettinen M: Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues. Hum. Pathol. 32(9), 976-983 (2001). (Pubitemid 32911321)
119. Boyle JL, Haupt HM, Stern JB, Multhaupt HA: Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch. Pathol. Lab. Med. 126(7), 816-822 (2002). (Pubitemid 34761639)
120. Fullen DR, Garrisi AJ, Sanders D, Thomas D: Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays. J. Cutan. Pathol. 35(Suppl. 2), 28-34 (2008).
121. Orchard GE: Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem. J. 32(8), 475-481 (2000).
122. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M: Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am. J. Surg. Pathol. 25(2), 205-211 (2001). (Pubitemid 32167502)
123. Mangini J, Li N, Bhawan J: Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am. J. Dermatopathol.24(3), 270-281 (2002). (Pubitemid 34587261)
124. Granter SR, Weilbaecher KN, Quigley C, Fisher DE: Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl. Immunohistochem. Mol. Morphol. 10(1), 47-51 (2002). (Pubitemid 34178276)
125. Slominski A, Tobin D, Shibahara S, Wortsman J: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84(4), 1155-228 (2004). (Pubitemid 39287950)
126. Sheffield MV, Yee H, Dorvault CC et al.: Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am. J. Clin. Pathol. 118(6), 930-936 (2002). (Pubitemid 37047834)
127. Blessing K, Sanders DS, Grant JJ: Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32(2), 139-146 (1998). (Pubitemid 28126180)
128. Plaza JA, Suster D, Perez-Montiel D: Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl. Immunohistochem. Mol. Morphol. 15(4), 421-425 (2007). (Pubitemid 350307848)
129. Mcnutt NS, Urmacher C, Hakimian J, Hoss DM, Lugo J: Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J. Cutan. Pathol. 22(6), 502-517 (1995). (Pubitemid 26013708)
130. Crotty KA, Scolyer RA, Li L, Palmer AA, Wang L, Mccarthy SW: Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology 34(1), 6-12 (2002). (Pubitemid 34155224)
131. Li LX, Crotty KA, Palmer AA et al.: Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation: a zonal comparison, correlation and multivariate analysis. Anal. Quant. Cytol. Histol. 24(4), 234-243 (2002).
132. Ribe A, Mcnutt NS: S100A6 protein expression is different in Spitz nevi and melanomas. Mod. Pathol. 16(5), 505-511 (2003). (Pubitemid 36618471)
133. Timar J, Udvarhelyi N, Banfalvi T, Gilde K, Orosz Z: Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies. Histopathology 44(2), 180-184 (2004). (Pubitemid 38296978)
134. Bottoni U, Izzo P, Richetta A et al.: S100 serum level: a tumour marker for metastatic melanoma. Melanoma Res. 13(4), 427-429 (2003). (Pubitemid 36900707)
135. Bouwhuis MG, Suciu S, Kruit W et al.: Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952 Eur. J. Cancer 47(3), 361-368 (2011).
136. Puri PK, Ferringer TC, Tyler WB, Wilson ML, Kirchner HL, Elston DM: Statistical analysis of the concordance of immunohistochemical stains with the final diagnosis in spitzoid neoplasms. Am. J. Dermatopathol. 33(1), 72-77 (2011).
137. Hendi A, Brodland DG, Zitelli JA: Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch. Dermatol. 142(7), 871-876 (2006). (Pubitemid 44079787)
138. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT: Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum. Pathol. 42(5), 618-631 (2011).
139. Pinczewski J, Slominski A: The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp. Dermatol. 19(10), 860-864 (2010).
140. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ: IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod. Pathol. DOI:101038/ modpathol.20115 (2011) (Epub ahead of print).
141. Wilsher M, Cheerala B: WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 51(5), 605-610 (2007). (Pubitemid 47572869)
142. Kashani-Sabet M, Rangel J, Torabian S et al.: A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc. Natl Acad. Sci. USA 106(15), 6268-6272 (2009).
143. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002). (Pubitemid 34587077)
144. Alonso SR, Ortiz P, Pollan M et al.: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 164(1), 193-203 (2004). (Pubitemid 38364604)
145. Hilliard NJ, Krahl D, Sellheyer K: p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J. Cutan. Pathol. 36(7), 753-759 (2009).
146. Mu XC, Tran TA, Ross JS, Carlson JA: Topoisomerase II-a expression in melanocytic nevi and malignant melanoma. J. Cutan. Pathol. 27(5), 242-248 (2000). (Pubitemid 30248967)
147. Rieger E, Hofmann-Wellenhof R, Soyer HP et al.: Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J. Cutan. Pathol. 20(3), 229-236 (1993). (Pubitemid 23210541)
148. Sparrow LE, English DR, Taran JM, Heenan PJ: Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am. J. Dermatopathol. 20(1), 12-16 (1998). (Pubitemid 28092700)
149. Bergman R, Malkin L, Sabo E, Kerner H: MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J. Am. Acad. Dermatol. 44(3), 500-504 (2001). (Pubitemid 32199972)
150. George E, Polissar NL, Wick M: Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors. Am. J. Clin. Pathol. 133(3), 370-379 (2010).
151. Maldonado JL, Timmerman L, Fridlyand J, Bastian BC: Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am. J. Pathol. 164(5), 1783-1787 (2004). (Pubitemid 38529780)
152. Korabiowska M, Betke H, Kellner S, Stachura J, Schauer A: Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanomas. Anticancer Res. 17(5A), 3697-3700 (1997). (Pubitemid 27522348)
153. Zucman J, Melot T, Desmaze C et al.: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. Embo J. 12(12), 4481-4487 (1993). (Pubitemid 23330254)
154. Bastian BC, Xiong J, Frieden IJ et al.: Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am. J. Pathol. 161(4), 1163-1169 (2002).
155. Maitra A, Gazdar AF, Moore TO, Moore AY: Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. Hum. Pathol. 33(2), 191-197 (2002). (Pubitemid 34298734)
156. Udart M, Utikal J, Krahn GM, Peter RU: Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3(3), 245-254 (2001). (Pubitemid 32747573)
157. Korabiowska M, Brinck U, Kotthaus I, Berger H, Droese M: Analysis of the DNA content in the progression of recurrent and metastatic melanomas. Anticancer Res. 20(4), 2791-2794 (2000). (Pubitemid 30614500)
158. Bastian BC, Olshen AB, Leboit PE, Pinkel D: Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol. 163(5), 1765-1770 (2003). (Pubitemid 37310008)
159. Leech SN, Bell H, Leonard N et al.: Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review of neonatal melanoma. Arch. Dermatol. 140(1), 83-88 (2004). (Pubitemid 38090274)
160. Scolyer RA, Prieto VG: Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. Surg. Oncol. Clin. N. Am. 20(1), 19-37 (2011).
161. Newman MD, Lertsburapa T, Mirzabeigi M, Mafee M, Guitart J, Gerami P: Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod. Pathol. 22(8), 989-995 (2009).
162. Newman MD, Mirzabeigi M, Gerami P: Chromosomal copy number changes supporting the classification of lentiginous junctional melanoma of the elderly as a subtype of melanoma. Mod. Pathol. 22(9), 1258-1262 (2009).
163. Pouryazdanparast P, Newman M, Mafee M, Haghighat Z, Guitart J, Gerami P: Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am. J. Surg. Pathol. 33(9), 1396-1400 (2009).
164. Dalton SR, Gerami P, Kolaitis NA et al.: Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am. J. Surg. Pathol. 34(2), 231-237 (2010).
165. Gerami P, Barnhill RL, Beilfuss BA, Leboit P, Schneider P, Guitart J: Superficial melanocytic neoplasms with pagetoid melanocytosis: a study of interobserver concordance and correlation with FISH. Am. J. Surg. Pathol. 34(6), 816-821 (2010).
166. Gerami P, Mafee M, Lurtsbarapa T, Guitart J, Haghighat Z, Newman M: Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch. Dermatol. 146(3), 273-278 (2010).
167. Gerami P, Pouryazdanparast P, Vemula S, Bastian BC: Molecular analysis of a case of nevus of ota showing progressive evolution to melanoma with intermediate stages resembling cellular blue nevus. Am. J. Dermatopathol. 32(3), 301-305 (2010).
168. Isaac AK, Lertsburapa T, Pathria Mundi J, Martini M, Guitart J, Gerami P: Polyploidy in spitz nevi: a not uncommon karyotypic abnormality identifiable by fluorescence in situ hybridization. Am. J. Dermatopathol. 32(2), 144-148 (2010).
169. Gammon B, Beilfuss B, Guitart J, Busam KJ, Gerami P: Fluorescence in situ hybridization for distinguishing cellular blue nevi from blue nevus-like melanoma. J. Cutan. Pathol. 38(4), 335-341 (2011).
170. Busam KJ, Fang Y, Jhanwar SC, Pulitzer MP, Marr B, Abramson DH: Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization. J. Cutan. Pathol. 37(2), 196-203 (2010).
171. Gerami P, Beilfuss B, Haghighat Z, Fang Y, Jhanwar S, Busam KJ: Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. J. Cutan. Pathol. 38(4), 329-334 (2011).
172. Vergier B, Prochazkova-Carlotti M, De La Fouchardiere A et al.: Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod. Pathol. 24(5), 613-623 (2011).
173. Gaiser T, Kutzner H, Palmedo G et al.: Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod. Pathol. 23(3), 413-419 (2010).
174. Massi D, Cesinaro AM, Tomasini C et al.: Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. J. Am. Acad. Dermatol. 64(5), 919-935 (2011).
175. North JP, Kageshita T, Pinkel D, Leboit PE, Bastian BC: Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J. Invest. Dermatol. 128(8), 2024-2030 (2008). (Pubitemid 352001223)
176. Gerami P, Jewell SS, Pouryazdanparast P et al.: Copy number gains in 11q13 and 8q34 are highly linked to prognosis in cutaneous malignant melanoma. J. Mol. Diagn. 13(3), 352-358 (2011).
177. Dickson PV, Gershenwald JE: Staging and prognosis of cutaneous melanoma. Surg. Oncol. Clin. N. Am. 20(1), 1-17 (2011).
178. Balch CM, Gershenwald JE, Soong SJ et al.: Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
179. Cormier JN, Xing Y, Feng L et al.: Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106(9), 2012-2020 (2006). (Pubitemid 43673218)
180. Lee CC, Faries MB, Wanek LA, Morton DL: Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 26(4), 535-541 (2008). (Pubitemid 351264345)
181. Pfeil AF, Leiter U, Buettner PG et al.: Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009 Melanoma Res. 21(3), 228-234 (2011).
182. Grob JJ, Richard MA, Gouvernet J et al.: The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int. J. Cancer 102(1), 34-38 (2002).
183. Liu W, Dowling JP, Murray WK et al.: Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch. Dermatol. 142(12), 1551-1558 (2006). (Pubitemid 44969210)
184. Tejera-Vaquerizo A, Lopez-Navarro N, Alcaide-Martin A, Herrera-Acosta E, Herrera-Ceballos E: Correlation of the growth rate of melanoma with the temporal appearance of metastasis. J. Eur. Acad. Dermatol. Venereol. 25(3), 366-337 (2011).
185. Bockmann B, Grill HJ, Giesing M: Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol. Eng. 17(3), 95-111 (2001). (Pubitemid 32143681)
186. Neagu M, Constantin C, Manda G, Margaritescu I: Biomarkers of metastatic melanoma. Biomark. Med. 3(1), 71-89 (2009).
187. Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK: Clinical node-negative thick melanoma. Arch. Surg. 137(3), 291-295 (2002). (Pubitemid 34207988)
188. Cascinelli N, Clemente C, Bifulco C et al.: Do patients with tumor-positive sentinel nodes constitute a homogeneous group? Ann. Surg. Oncol. 8(Suppl. 9), 35S-37S (2001).
189. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U: Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol. 38(5), 549-557 (1999). (Pubitemid 29333734)
190. Tejera-Vaquerizo A, Barrera-Vigo MV, Fernandez-Canedo I et al.: [Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma]. Actas Dermosifiliogr. 98(8), 531-538 (2007). (Pubitemid 47596706)
191. Gershenwald JE, Thompson W, Mansfield PF et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. 17(3), 976-983 (1999). (Pubitemid 29109331)
192. Cascinelli N, Bombardieri E, Bufalino R et al.: Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J. Clin. Oncol. 24(27), 4464-4471 (2006). (Pubitemid 46630985)
193. Ross MI, Thompson JF, Gershenwald JE: Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. Surg. Oncol. Clin. N. Am. 20(1), 57-78 (2011).
194. Rhodes AR: Prognostic usefulness of sentinel lymph node biopsy for patients who have clinically node negative, localized, primary invasive cutaneous melanoma: a Bayesian analysis using informative published reports. Arch. Dermatol. 147(4), 408-415 (2011).
195. Sartore L, Papanikolaou GE, Biancari F, Mazzoleni F: Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node. Int. J. Surg. 6(3), 205-209 (2008).
196. Wong SL, Kattan MW, Mcmasters KM, Coit DG: A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann. Surg. Oncol. 12(4), 282-288 (2005). (Pubitemid 40616492)
197. Niakosari F, Kahn HJ, Mccready D et al.: Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch. Dermatol. 144(4), 462-467 (2008). (Pubitemid 351581102)
198. Massi D, Puig S, Franchi A et al.: Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J. Clin. Pathol. 59(2), 166-173 (2006). (Pubitemid 43235582)
199. Rangel J, Nosrati M, Torabian S et al.: Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1), 144-150 (2008).
200. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR 3rd, Leong SP: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch. Dermatol. 134(8), 983-987 (1998). (Pubitemid 28385320)
201. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS: Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 25(7), 869-875 (2007). (Pubitemid 350002888)
202. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T: The nodal location of metastases in melanoma sentinel lymph nodes. Am. J. Surg. Pathol. 33(10), 1522-1528 (2009).
203. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T: Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes: the protocol trap. Cancer 115(10), 2177-2187 (2009).
204. Murali R, Thompson JF, Scolyer RA: Location of melanoma metastases in sentinel lymph nodes: what are the implications for histologic processing of sentinel lymph nodes in routine practice? Am. J. Surg. Pathol. 34(1), 127-129; author reply 129-131 (2010).
205. Shivers SC, Wang X, Li W et al.: Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280(16), 1410-1415 (1998). (Pubitemid 28496047)
206. Wang X, Heller R, Vanvoorhis N et al.: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann. Surg. 220(6), 768-774 (1994). (Pubitemid 24376375)
207. Kammula US, Ghossein R, Bhattacharya S, Coit DG: Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction - staged sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 22(19), 3989-3996 (2004). (Pubitemid 41079882)
208. Scoggins CR, Ross MI, Reintgen DS et al.: Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J. Clin. Oncol. 24(18), 2849-2857 (2006). (Pubitemid 46630585)
209. Giuliano AE, Hunt KK, Ballman KV et al.: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6), 569-575 (2011).
210. Morton DL, Thompson JF, Cochran AJ et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355(13), 1307-1317 (2006). (Pubitemid 44465459)
211. Kunte C, Geimer T, Baumert J et al.: Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. J. Am. Acad. Dermatol. 64(4), 655-662 (2011).
212. Wilson JP, Mattson D, Edge SB: Is there a need for axillary dissection in breast cancer? J. Natl Compr. Canc. Netw. 9(2), 225-230 (2011).
213. Viros A, Fridlyand J, Bauer J et al.: Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5(6), e120 (2008).
214. Broekaert SM, Roy R, Okamoto I et al.: Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 23(6), 763-770 (2010).
215. Long GV, Menzies AM, Nagrial AM et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29(10), 1239-1246 (2011).
216. Carlson JA, Ross J, Murphy M: Markers of high-risk cutaneous melanoma: is there a winning combination for individualized prognosis? J. Cutan. Pathol. 32(10), 700-703 (2005). (Pubitemid 41719752)
217. Gould Rothberg BE, Berger AJ, Molinaro AM et al.: Melanoma prognostic model using tissue microarrays and genetic algorithms. J. Clin. Oncol. 27(34), 5772-5780 (2009).
218. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK).Nat. Clin. Pract. Urol. 2(8), 416-422 (2005). (Pubitemid 43115010)
219. Bedin V, Adam RL, De Sa BC, Landman G, Metze K: Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC Cancer 10(1), 260 (2010).
220. Healy E, Belgaid C, Takata M et al.: Prognostic significance of allelic losses in primary melanoma. Oncogene 16(17), 2213-2218 (1998). (Pubitemid 28220651)
221. Daniotti M, Oggionni M, Ranzani T et al.: BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23(35), 5968-5977 (2004). (Pubitemid 39093541)
222. Krouse RS, Alberts DS, Prasad AR et al.: Progression of skin lesions from normal skin to squamous cell carcinoma. Anal. Quant. Cytol. Histol. 31(1), 17-25 (2009).
223. Cremer T, Cremer C: Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat. Rev. Genet. 2(4), 292-301 (2001). (Pubitemid 33674777)
224. Balch CM, Gershenwald JE, Soong SJ et al.: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28(14), 2452-2459 (2010).
225. Leiter U, Meier F, Schittek B, Garbe C: The natural course of cutaneous melanoma. J. Surg. Oncol. 86(4), 172-178 (2004). (Pubitemid 38880283)
226. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE: The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J. Clin. Oncol. 23(21), 4588-4590 (2005).
227. Bedikian AY, Johnson MM, Warneke CL et al.: Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 26(6), 624-633 (2008). (Pubitemid 351918588)
228. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 181(3), 193-201 (1995).
229. Staudt M, Lasithiotakis K, Leiter U et al.: Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102(8), 1213-1218 (2010).
230. Lee ML, Tomsu K, Von Eschen KB: Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 10(1), 81-92 (2000). (Pubitemid 30127833)
231. Dummer R, Garbe C, Thompson JA et al.: Randomized dose-escalation study evaluating peginterferon a-2a in patients with metastatic malignant melanoma. J. Clin. Oncol. 24(7), 1188-1194 (2006). (Pubitemid 46638817)
232. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297(5578), 63-64 (2002). (Pubitemid 34743088)
233. Brown E, Lewis PH, Nocera J: In search of the silver bullet. Fortune 143(10), 166-170, 172, 174 passim (2001).
234. Lemonick MD, Park A: New hope for cancer. Time 157(21), 62-69 (2001).
235. Miller AJ, Mihm MC Jr: Melanoma. N. Engl. J. Med. 355(1), 51-65 (2006).
236. Kalinsky K, Haluska FG: Novel inhibitors in the treatment of metastatic melanoma. Expert Rev. Anticancer Ther. 7(5), 715-724 (2007). (Pubitemid 46805566)
237. Lejeune FJ, Rimoldi D, Speiser D: New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev. Anticancer Ther. 7(5), 701-713 (2007). (Pubitemid 46805565)
238. Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002). (Pubitemid 34716871)
239. Hocker T, Tsao H: Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 28(6), 578-588 (2007). (Pubitemid 46744288)
240. Garnett MJ, Rana S, Paterson H, Barford D, Marais R: Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20(6), 963-969 (2005). (Pubitemid 41814884)
241. Hauschild A, Agarwala SS, Trefzer U et al.: Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27(17), 2823-2830 (2009).
242. Flaherty KT, Puzanov I, Kim KB et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
243. Nazarian R, Shi H, Wang Q et al.: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010).
244. Johannessen CM, Boehm JS, Kim SY et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968-972 (2010).
245. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA: BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal 3(149), ra84 (2010).
246. Villanueva J, Vultur A, Lee JT et al.: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/ PI3K. Cancer Cell 18(6), 683-695 (2010).
247. Hatzivassiliou G, Song K, Yen I et al.: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287), 431-435 (2010).
248. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427-430 (2010).
249. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9(17), 6483-6488 (2003). (Pubitemid 38031837)
250. Edlundh-Rose E, Egyhazi S, Omholt K et al.: NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 16(6), 471-478 (2006). (Pubitemid 44934704)
251. Martorell-Calatayud A, Requena C, Botella-Estrada R, Sangueza OP: [Advances in molecular biology and their application in the diagnosis and treatment of melanoma]. Actas Dermosifiliogr. 100(Suppl. 1), 52-65 (2009).
252. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA: Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J. Invest. Dermatol. 129(6), 1483-1488 (2009).
253. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6(7), 541-555 (2007). (Pubitemid 47019443)
254. Zhang FL, Kirschmeier P, Carr D et al.: Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem. 272(15), 10232-10239 (1997). (Pubitemid 27171703)
255. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002). (Pubitemid 37328931)
256. Mirmohammadsadegh A, Marini A, Nambiar S et al.: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66(13), 6546-6552 (2006). (Pubitemid 44085609)
257. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22(20), 3113-3122 (2003). (Pubitemid 36713763)
258. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG: Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126(1), 154-160 (2006). (Pubitemid 43336107)
259. Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28(6), 1075-1083 (2010).
260. Margolin K, Longmate J, Baratta T et al.: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104(5), 1045-1048 (2005). (Pubitemid 41170233)
261. Chresta CM, Davies BR, Hickson I et al.: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70(1), 288-298 (2010).
262. Jaiswal BS, Janakiraman V, Kljavin NM et al.: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 4(5), E5717 (2009).
263. Beadling C, Jacobson-Dunlop E, Hodi FS et al.: KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14(21), 6821-6828 (2008).
264. Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem. Pharmacol. 80(5), 568-574 (2010).
265. Hodi FS, Friedlander P, Corless CL et al.: Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26(12), 2046-2051 (2008).
266. Woodman SE, Trent JC, Stemke-Hale K et al.: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 8(8), 2079-2085 (2009).
267. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat. Clin. Pract. Oncol. 5(12), 737-740 (2008).
268. Kluger HM, Dudek AZ, Mccann C et al.: A Phase 2 trial of dasatinib in advanced melanoma. Cancer 117(10), 2202-2208 (2011).
269. Van Raamsdonk CD, Bezrookove V, Green G et al.: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229), 599-602 (2009).
270. Onken MD, Worley LA, Long MD et al.: Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49(12), 5230-5234 (2008).
271. Van Raamsdonk CD, Griewank KG, Crosby MB et al.: Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363(23), 2191-2199 (2010).
272. Downey SG, Klapper JA, Smith FO et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681-6688 (2007). (Pubitemid 350206804)
273. Weber JS, O'day S, Urba W et al.: Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950-5956 (2008).
274. Beck KE, Blansfield JA, Tran KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J. Clin. Oncol. 24(15), 2283-2289 (2006). (Pubitemid 46630658)
275. Peggs KS, Quezada SA: Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev. Anticancer Ther. 10(11), 1697-1701 (2010).
276. Hodi FS, O'day SJ, Mcdermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
277. Mcdermott DF, Sosman JA, Gonzalez R et al.: Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26(13), 2178-2185 (2008).
278. Camacho LH, Antonia S, Sosman J et al.: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075-1081 (2009).
279. Brahmer JR, Drake CG, Wollner I et al.: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
280. Winfield HL, Kirkland F, Ramos-Ceballos FI, Horn TD: Osteopontin expression in spitz nevi. Arch. Dermatol. 143(8), 1076-1077 (2007).
281. Svobodova S, Browning J, Macgregor D et al.: Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur. J. Cancer 47(3), 460-469 (2011).